Skin
- (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic,
Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients
with Advanced Solid Tumors
-
(107-19) A Study of TRK-950 in Combinations With Anti-Cancer Treatment
Regimens in Patients With Advanced Solid Tumors (Phase 1b clinical trial, appropriate for patients with Nivolumab or Pembrolizumab
as standard of care.)
-
(131-17) A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01) (Phase 1 clinical trial, appropriate for patients with all solid tumors.)
-
(157-17) FID-007 in Treating Participants With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid
malignancies.)
- (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity
of ASTX029 in Subjects With Advanced Solid Tumors
-
(183-19) A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab
in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment (Phase 1/2a clinical trial, appropriate for patients with metastatic melanoma.)
-
(187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal
Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1
Monoclonal Antibody, in Subjects with Advanced Cancer (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
-
(189-18) ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With
Metastatic Solid Tumors (Phase 2 clinical trial, appropriate for patients with metastatic solid tumors.)
-
(201-19) A Phase 1 Study of AGEN1223, a Bispecific Fc-Engineered Anti-GITR-OX40
Antibody in Subjects with Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
-
(221-19) Study of GNX102 in Patients With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
Certain clinical trials may not be listed on ClinicalTrials.gov. To learn
more about these or other clinical trials, please call 949-764-5543 or
contact us online.